Dubai mother takes on 150km camel challenge for six-year-old son with Angelman syndrome

Dubai mom embarks on a 150km camel journey to raise awareness for Angelman syndrome, inspired by her son's resilience and ...
Sentient Media

What the History of Blue Baby Syndrome Tells Us About Today’s Fight for Clean Water

Then came the vomiting and crying. She wasn’t gaining weight. Her parents took her to the hospital, and again a few days ...
Hosted on MSN

Boys with Angelman syndrome share a warm embrace

Two friends show their excitement at seeing each other with a heartfelt hug. 4 subtle stroke warning signs that should never be ignored Watch this Komodo dragon kill prey 3x its size... it doesn’t let ...
Medical Daily

A Gene Targeting Therapy for Angelman Syndrome Failed Its Final Trial, Leaving Families Without an Approved Option

A BMJ study of 624,713 Swedish births linked HPV vaccination before pregnancy to 15% lower odds of very preterm birth. What families should know. Novo Nordisk and Eli Lilly say GLP-1 drugs slowed ...
STAT

After failure of Angelman syndrome drug, experts see hope in other experimental therapies

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. The failure of an experimental drug for ...
The Business Journals

Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's stock closed down ...
Seeking Alpha

Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist

The stock of Novato, California-based biotech company Ultragenyx Pharmaceutical (RARE), a specialist developer of medicines to treat serious rare and ultra-rare genetic diseases, has tumbled in value ...
MedCity News

Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder

The rare neurological disorder Angelman syndrome leads to a range of developmental and movement problems in children, who have no FDA-approved therapeutic options. A closely watched Ultragenyx ...
Yahoo Finance

Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Reuters

Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial

Stock hits a record low, risking about $1.25 billion in market value At least 10 brokerages cut price targets after the data Ultragenyx plans significant expense cuts Sept 3 (Reuters) - Shares of ...
FierceBiotech

Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’

Analysts at William Blair were “disappointed” by the data but said they had always viewed Ultragenyx's trial as “high risk, high reward.” (iStock / Getty Images Plus) Ultragenyx had been flying high ...
STAT

Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. The biotech company Ultragenyx said ...